Report cover image

Europe Fill Finish Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report By Product (Prefilled Syringes, Vials, Cartridges), By Molecule, By End Use, By Region, And Segment Forecasts, 2025 - 2030

Published Nov 28, 2024
Length 100 Pages
SKU # GV21020407

Description

Europe Fill Finish Pharmaceutical Contract Manufacturing Market Growth & Trends

The Europe fill finish pharmaceutical contract manufacturing market size is expected to reach USD 9.54 billion by 2030, expanding at a CAGR of 8.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by factors such as the increasing demand for sterile injectable drugs, the rising prevalence of chronic diseases, and the growing focus on cost containment and efficiency by pharmaceutical companies. Additionally, advancements in technology and the increasing use of contract manufacturing by pharmaceutical companies are expected to drive market growth.

The Europe fill finish pharmaceutical contract manufacturing market is also characterized by a number of trends, such as the growing importance of regulatory compliance, the increasing use of single-use technology, and the rising adoption of advanced analytical and quality control systems. Additionally, there is a growing trend towards the use of contract manufacturing by small and mid-sized pharmaceutical companies, as well as by virtual biotech companies.

Germany dominated the market in 2024 owing to a strong base of biotechnology and pharmaceutical companies in the region. These companies are involved in drug discovery activities, which, in turn, led to the growth of the market in the region. The COVID-19 pandemic has had a significant impact, and one of the major impacts of the pandemic on the fill-finish contract manufacturing market in Europe has been an increased demand for COVID-19 vaccines and therapies. This has aided in increasing the demand for CMOs in the market since the fill-finish process requires advanced technology; thus, to reduce the cost, many Pharma and Biotech companies are more focused on outsourcing the fill-finish process, thereby boosting the overall market growth.

Europe Fill Finish Pharmaceutical Contract Manufacturing Market Report Highlights
  • On the basis of product type, Vials dominated the market and accounted for a share of 53.4% in 2024 and Prefilled syringes are expected to grow at the fastest CAGR of 9.6% over the forecast period.
  • Based on the Molecule type, the small molecule segment dominated the market in 2022 with the largest share of 67.3% in 2024 and is anticipated to show lucrative growth over the forecast period.
  • Based on the End-use segment, the biopharmaceutical segment dominated the market and accounted for the largest revenue share of 35.9% in 2024. The increasing demand for biologics and biosimilars is driving the growth of the biopharmaceutical end-use segment. Due to the market for biologics and biosimilars experiencing rapid expansion, biopharmaceutical companies are the main consumers of fill-finish contract manufacturing services.
  • The UK fill-finish pharmaceutical contract manufacturing market held the largest market share of 20.3% in 2024 in the Europe market and the fill-finish pharmaceutical contract manufacturing market in Germany is expected to grow at the fastest CAGR of 11.0% over the forecast period.
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

100 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Molecule
1.2.3. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Europe Fill-finish Pharmaceutical Contract Manufacturing Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Europe Fill-finish Pharmaceutical Contract Manufacturing Market: Product Business Analysis
4.1. Product Market Share, 2024 & 2030
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Prefilled Syringes
4.4.1. Prefilled Syringes Market, 2018 - 2030 (USD Million)
4.5. Vials
4.5.1. Vials Market, 2018 - 2030 (USD Million)
4.6. Cartridges
4.6.1. Cartridges Market, 2018 - 2030 (USD Million)
4.7. Others
4.7.1. Others Market, 2018 - 2030 (USD Million)
Chapter 5. Europe Fill-finish Pharmaceutical Contract Manufacturing Market: Molecule Business Analysis
5.1. Molecule Market Share, 2024 & 2030
5.2. Molecule Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Molecule, 2018 to 2030 (USD Million)
5.4. Large Molecules
5.4.1. Large Molecules Market, 2018 - 2030 (USD Million)
5.5. Small Molecules
5.5.1. Small Molecules Market, 2018 - 2030 (USD Million)
Chapter 6. Europe Fill-finish Pharmaceutical Contract Manufacturing Market: End Use Business Analysis
6.1. End Use Market Share, 2024 & 2030
6.2. End Use Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
6.4. Biopharmaceutical Companies
6.4.1. Biopharmaceutical Companies Market, 2018 - 2030 (USD Million)
6.5. Pharmaceutical Companies
6.5.1. Pharmaceutical Companies Market, 2018 - 2030 (USD Million)
Chapter 7. Europe Fill-finish Pharmaceutical Contract Manufacturing Market: Country Estimates & Trend Analysis by Product, Molecule, and End Use
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. UK
7.4.1. Key Country Dynamics
7.4.2. Regulatory Framework
7.4.3. Competitive Insights
7.4.4. UK Fill-finish Pharmaceutical Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5. Germany
7.5.1. Key Country Dynamics
7.5.2. Regulatory Framework
7.5.3. Competitive Insights
7.5.4. Germany Fill-finish Pharmaceutical Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6. France
7.6.1. Key Country Dynamics
7.6.2. Regulatory Framework
7.6.3. Competitive Insights
7.6.4. France Fill-finish Pharmaceutical Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.7. Italy
7.7.1. Key Country Dynamics
7.7.2. Regulatory Framework
7.7.3. Competitive Insights
7.7.4. Italy Fill-finish Pharmaceutical Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.8. Spain
7.8.1. Key Country Dynamics
7.8.2. Regulatory Framework
7.8.3. Competitive Insights
7.8.4. Spain Fill-finish Pharmaceutical Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.9. Norway
7.9.1. Key Country Dynamics
7.9.2. Regulatory Framework
7.9.3. Competitive Insights
7.9.4. Norway Fill-finish Pharmaceutical Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.10. Denmark
7.10.1. Key Country Dynamics
7.10.2. Regulatory Framework
7.10.3. Competitive Insights
7.10.4. Denmark Fill-finish Pharmaceutical Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.11. Sweden
7.11.1. Key Country Dynamics
7.11.2. Regulatory Framework
7.11.3. Competitive Insights
7.11.4. Sweden Fill-finish Pharmaceutical Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Thermo Fisher Scientific Inc.
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Sartorius AG
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Boehringer Ingelheim International GmbH
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Catalent, Inc (acquired by Novo Holdings A/S)
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Societal CDMO (Recro Pharma, Inc)
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Baxter
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Eurofins Scientific
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Symbiosis Pharmaceutical Services Ltd
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. MabPlex International Co. Ltd.
8.5.9.1. Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Recipharm AB
8.5.10.1. Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
8.5.11. Fresenius Kabi, USA LLC
8.5.11.1. Overview
8.5.11.2. Financial Performance
8.5.11.3. Product Benchmarking
8.5.11.4. Strategic Initiatives
8.5.12. Lonza
8.5.12.1. Overview
8.5.12.2. Financial Performance
8.5.12.3. Product Benchmarking
8.5.12.4. Strategic Initiatives
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.